The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean ± SD 8.68 ± 1.0 g/dL at baseline vs. 9.83 ± 1.45, 9.99 ± 1.55, 10.24 ± 1.77 and 10.2 ± 1.5...
Source: Indian Journal of Hematology and Blood Transfusion - June 26, 2021 Category: Hematology Source Type: research
Continuous optical in-line glucose monitoring and control in CHO cultures contributes to enhanced metabolic efficiency while maintaining darbepoetin alfa product quality
This article is protected by copyright. All rights reserved.PMID:34008350 | DOI:10.1002/biot.202100088 (Source: Biotechnology Journal)
Source: Biotechnology Journal - May 19, 2021 Category: Biotechnology Authors: Mario Lederle Mircea Tric Tatjana Roth Lina Sch ütte Anke Rattenholl Dirk L ütkemeyer Stefan W ölfl Tobias Werner Philipp Wiedemann Source Type: research
Continuous optical in-line glucose monitoring and control in CHO cultures contributes to enhanced metabolic efficiency while maintaining darbepoetin alfa product quality
This article is protected by copyright. All rights reserved.PMID:34008350 | DOI:10.1002/biot.202100088 (Source: Biotechnology Journal)
Source: Biotechnology Journal - May 19, 2021 Category: Biotechnology Authors: Mario Lederle Mircea Tric Tatjana Roth Lina Sch ütte Anke Rattenholl Dirk L ütkemeyer Stefan W ölfl Tobias Werner Philipp Wiedemann Source Type: research
Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells
Publication date: Available online 31 March 2021Source: Toxicology ReportsAuthor(s): Michele Andreucci, Michele Provenzano, Teresa Faga, Ida Gagliardi, Antonio Pisani, Maria Perticone, Giuseppe Coppolino, Giovambattista De Sarro, Raffaele Serra, Ashour Michael (Source: Toxicology Reports)
Source: Toxicology Reports - April 1, 2021 Category: Toxicology Source Type: research
IJERPH, Vol. 17, Pages 9562: Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement
In conclusion, we identified areas for improvement in MDS patient care, in need of further clinical trials, information, and guiding documents. (Source: International Journal of Environmental Research and Public Health)
Source: International Journal of Environmental Research and Public Health - December 21, 2020 Category: Environmental Health Authors: Ioannis Chanias C. Wilk Rudolf Benz Michael Daskalakis Georg St üssi Adrian Schmidt Ulrike Bacher Nicolas Bonadies on behalf of the Swiss MDS Study Group Tags: Article Source Type: research
Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program
ConclusionREMS program implementation and enforcement were not associated with significant changes in ESA initiation, adding to concerns over the degree to which certain REMS programs enhance patient safety. (Source: Drug Safety)
Source: Drug Safety - November 18, 2020 Category: Drugs & Pharmacology Source Type: research
CERA conversion to darbepoetin alfa in 154 hemodialysis patients
ConclusionsWe conclude that, in this observational “real life” study, the two EPOs are to be considered as equivalent. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - September 24, 2020 Category: Urology & Nephrology Source Type: research
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
ConclusionsNon-responder to DA accounted for 13.3% of patients with non-dialysis CKD. Iron supplementation, low CRP, low NT-proBNP, and less proteinuria were predictive and modifiable factors associated with better initial response to DA. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - September 18, 2020 Category: Urology & Nephrology Source Type: research
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
CONCLUSIONS: Oral daprodustat was noninferior to darbepoetin alfa as measured by mean hemoglobin over weeks 40-52 in Japanese patients receiving hemodialysis switched from ESAs.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: 201754, Clinicaltrials.gov, NCT02969655.
PMID: 32723804 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 27, 2020 Category: Urology & Nephrology Authors: Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR Tags: Clin J Am Soc Nephrol Source Type: research
A pharmacist ‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
In conclusion, a pharmacist‐managed dosing algorithm for DA and iron sucrose increased the attainment of target levels for hemoglobin and iron stat us, reduced the percentage of high hemoglobin levels, and was associated with a lower DA and a higher iron sucrose dose. (Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - July 25, 2020 Category: Drugs & Pharmacology Authors: Francisca Johanna Oever,
Carolien F. M. Heetman ‐Meijer,
Erwin Birnie,
Erwin C. Vasbinder,
Eleonora L. Swart,
Yvonne C. Schrama Tags: ORIGINAL ARTICLE Source Type: research
Small Bowel Pseudomelanosis
A 78-year-old woman with a history of type 2 diabetes mellitus, chronic kidney disease stage 4, hypertension, atrial fibrillation, grade 1 follicular lymphoma, gastroesophageal reflux disease, and iron deficiency anemia presented with several months of transfusion-dependent anemia. Medications included oral ferrous sulfate, insulin, spironolactone, clonidine, metoprolol, simvastatin, omeprazole, and apixaban. In the past several months, she had been receiving weekly darbepoetin alfa injections and requiring 4 blood transfusions a month. (Source: Mayo Clinic Proceedings)
Source: Mayo Clinic Proceedings - June 30, 2020 Category: Internal Medicine Authors: Hyun Ji, Zongming E. Chen, Sunanda V. Kane Tags: Medical image Source Type: research
Disappearance of monosomy 7 in a patient with aplastic anemia after eltrombopag treatment.
We present the case of a patient with aplastic anemia (AA) who was treated with eltrombopag. To the best of our knowledge, this is the first report of the disappearance of monosomy 7 after eltrombopag treatment. The patient was a 77-year-old woman with intraoral hematoma and purpura who was diagnosed with very severe AA with a normal karyotype. After combination therapy with rabbit antithymocyte globulin, cyclosporin, and granulocyte-colony-stimulating factor (G-CSF), pancytopenia transiently improved. When pancytopenia worsened again, the patient was administered darbepoetin alfa for renal anemia and danazol. Bone marrow ...
Source: Hematology - April 29, 2020 Category: Hematology Tags: Hematology Source Type: research
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
CONCLUSIONS: Targeting a higher hemoglobin level (11-13 g/dl) with darbepoetin alfa did not improve kidney outcome compared with targeting a lower hemoglobin level (9-11 g/dl) in patients with advanced CKD without diabetes.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Prevention of ESKD by Darbepoetin Alfa in CKD Patients with Non-diabetic Kidney Disease (PREDICT), NCT01581073.
PMID: 32245781 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 2, 2020 Category: Urology & Nephrology Authors: Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators Tags: Clin J Am Soc Nephrol Source Type: research
Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy
Somanath Padhi, Gayatri Behera, Sandeep Abhijit Pattnaik, Prabodh Kumar Das, Amit Kumar Adhya, Susama PatraIndian Journal of Nephrology 2020 30(2):113-116
Acquired pure red cell aplasia (PRCA) following use of recombinant erythropoietin (rEPO) is distinctly rare and sporadically reported in the literature. We discuss a case of PRCA following the usage of rEPO (darbepoetin-α) during the management of anemia of chronic kidney disease in an elderly male subject with review of literature and a brief insight into proposed pathophysiologic mechanism, diagnosis, and management. (Source: Indian Journal of Nephrology)
Source: Indian Journal of Nephrology - March 3, 2020 Category: Urology & Nephrology Authors: Somanath Padhi Gayatri Behera Sandeep Abhijit Pattnaik Prabodh Kumar Das Amit Kumar Adhya Susama Patra Source Type: research
